Koers Brainstorm Cell Therapeutics Inc OTC Bulletin Board
Aandelen
US10501E2019
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 30,34 mln. 28,27 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -21 mln. -19,57 mln. | Nettowinst (verlies) 2025 * | -27 mln. -25,16 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-1,55
x | K/w-verhouding 2025 * |
-1,15
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 86,62% |
Recentste transcriptie over Brainstorm Cell Therapeutics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chaim Lebovits
CEO | Chief Executive Officer | 53 | 01-07-07 |
Alla Patlis
DFI | Director of Finance/CFO | 37 | 23-12-12 |
Chief Tech/Sci/R&D Officer | - | 12-05-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Irit Arbel
FOU | Founder | 64 | 22-09-00 |
Uri Yablonka
BRD | Director/Board Member | 47 | 06-06-14 |
Jacob Frenkel
CHM | Chairman | 81 | 30-03-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+49,41% | 56,95 mld. | |
+40,26% | 40,26 mld. | |
-6,72% | 39,32 mld. | |
-5,96% | 28,37 mld. | |
+12,99% | 26,45 mld. | |
-19,82% | 19,41 mld. | |
+32,35% | 12,54 mld. | |
-0,08% | 12,15 mld. | |
+25,18% | 12,21 mld. |
- Beurs
- Aandelen
- Koers BCLI
- Koers